CARL ICAHN owns 1.4% of Illumina, a genomics giant with a market value of $34bn. Mr Icahn’s modest stake belies his ambition. As the elder statesman of activist investing, the 87-year-old aims to convert small shareholdings into considerable influence. Mr Icahn has nominated three directors to the board of Illumina, whose share price has fallen by 60% since its peak in 2021, in part owing to hubristic dealmaking. On May 25th, after The…